GENDYSFIB: Genomics of Fibrin Clot Structure in Patients With Constitutional Dysfibrinogenemia
Study Details
Study Description
Brief Summary
Hereditary dysfibrinogenemia results from monoallelic mutation in one of the fibrinogen genes (FGA, FGB, FGG). The spectrum of molecular abnormalities is broad, leading to several subtypes of coagulation disorders with specific biological and clinical features. The correlation between the genotype and the phenotype is poor, and the clinical course of patients, from major bleeding to recurrent thromboses, is unpredictable. Fibrin clot structure is a determinant of the risk of thrombosis in cardiovascular diseases. In all individuals, fibrin networks define the propensity of clot to be more resistant to removal or, on the contrary, susceptible to fragmentation leading to bleeding complications. Besides fibrinogen variants, other relatively common genetic polymorphisms in coagulation and fibrinolytic pathways may affect the fibrin clot structure and therefore act as modifiers of the blood clot function.
In this proposal, the investigators will analyze properties (polymerization, fibrinolysis, viscoelastic properties, permeation) and ultrastructure (size, number, packaging, architecture of fibrin fiber by confocal microscopy and scanning electron microscopy) of plasma-based clots in relation to the presence of genetic modifiers (polymorphisms). Polymorphisms will be detected using a whole exome sequencing (WES) in a selected panel of genes of the coagulation and fibrinolytic pathways. The gene panel of 28 genes will include the three fibrinogen genes plus 25 potential modifier genes including F5, F2, PAI-1, PROCR and MTHFR. The overall clot phenotype will be correlated to the presence of prothrombotic polymorphisms and to the patient's clinical phenotype. The investigators plan to include about 100 patients with dysfibrinogenemia. The combination of integrative hemostasis models with genetic dataset will provide a global view of the patient's individual hemostatic profile. This may allow to better predict the clinical outcome and help provide a more personalized therapeutic strategy and precision medicine. In addition, the development of models allowing a reliable global assessment of fibrin clot architecture will be the basis for further research in other acquired diseases involving thrombotic or bleeding events.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Patients with hereditary dysfibrinogenemia Patient, male or female, aged over 18, with confirmed hereditary dysfibrinogenemia |
Biological: Blood test
For each patient included, this study will involve the collection of 20 ml of blood during a blood test carried out as part of routine care. One EDTA tube (4,5 ml) will be withdrawn and frozen for genetic testing. 15 ml of citrated blood sample (3 to 5 tubes, depending on the used tubes) are necessary for the study of fibrin clot structure. Citrated tubes will be double centrifugated and frozen (-80°C) according to Groupe Français d'Études sur l'Hémostase et la thrombose guidelines (centrifugation protocol: 1500 to 2000g at least 15min, or 2000 to 2500g at least 10min with an intermediate decantation).
|
Outcome Measures
Primary Outcome Measures
- relation between the genetic polymorphisms and the main parameters of each different tools evaluating the ultrastructure of fibrin clot [at the end of the inclusion periode]
High quality genomic DNA will be purified using standard procedures and quantified using the Thermo Fisher Qubit fluorometric quantification. Whole exome sequencing will be performed at the Health 2030 Genome Center, Campus Biotech, Geneva using IDT Research Exome Reagents, multiplexing 12 samples during library preparation, for a mean coverage of 70x
Secondary Outcome Measures
- relation between the genetic polymorphisms and the clinical phenotype of patients with dysfibrinogenemia (thrombotic and/or bleeding phenotype) [at the end of the inclusion periode]
- relation between the main parameters of ultrastructure of fibrin clot properties and the clinical phenotype of patients with dysfibrinogenemia [at the end of the inclusion periode]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patient with confirmed hereditary dysfibrinogenemia
-
Able to give his/her informed consent to participate
-
Affiliated to the French Health insurance
Exclusion Criteria:
-
Refusal to participate
-
pregnant and breastfeeding women,
-
protected adults (individuals under guardianship by court order),
-
adults deprived of their liberty
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | CHU clermont-ferrand | Clermont-Ferrand | France | ||
| 2 | CHU Dijon | Dijon | France | ||
| 3 | CHU de Lille | Lille | France | ||
| 4 | CHU Montpellier | Montpellier | France | ||
| 5 | CHu Nancy | Nancy | France | ||
| 6 | CHU Nantes | Nantes | France | ||
| 7 | CHU Tours | Tours | France |
Sponsors and Collaborators
- University Hospital, Clermont-Ferrand
Investigators
- Principal Investigator: Aurélien LEBRETON, University Hospital, Clermont-Ferrand
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- RNI 2021 LEBRETON
- 2021-A00745-36